Subscribe to an RSS Feed Reports:
Valeant Pharmaceuticals International (VRX):
|
Don't see the Scenario report you want?
- Competitors by Product for Valeant Pharmaceuticals International (VRX) Exact product by product comparables to each of a company's competitors which trade on a major US exchange. Revere - Aug 21, 2010 - HTML - $75.00 - Add to Cart »
- Drug/Medical Device for Valeant Pharmaceuticals International (VRX) The most complete and accurate coverage of a company's FDA approved products and pipeline candidates. Revere - Sep 04, 2010 - PDF - $70.00 - Add to Cart »
- FDA Approval Decisions Report for August, 2010 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Aug 01, 2010 - ZIP - $125.00 - Add to Cart »
- FDA Approval Decisions Report for July, 2010 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Jul 01, 2010 - ZIP - $125.00 - Add to Cart »
- FDA Approval Decisions Report for June, 2010 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Jun 01, 2010 - ZIP - $125.00 - Add to Cart »
- FDA Approval Decisions Report for September, 2010 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Sep 01, 2010 - ZIP - $125.00 - Add to Cart »
- Merger and Acquisition Scenario for APP Pharmaceuticals, Inc. (APPX) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Sep 13, 2008 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for Abbott Laboratories (ABT) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Aug 21, 2010 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for Abraxis Bioscience, Inc. (ABII) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - May 30, 2009 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for Acambis plc (ADR) (ACAM) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Mar 11, 2006 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for Adams Respiratory Therapeutics, Inc. (ARXT) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Oct 20, 2007 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for Alexion Pharmaceuticals, Inc. (ALXN) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Nov 28, 2009 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for Allergan, Inc. (AGN) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Aug 21, 2010 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for Alnylam Pharmaceuticals, Inc. (ALNY) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Feb 16, 2008 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for Alpharma Inc. (ALO) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Dec 27, 2008 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for Altana AG (ADR) (AAA) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Dec 16, 2006 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for Amgen, Inc. (AMGN) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Sep 12, 2009 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for Amylin Pharmaceuticals, Inc. (AMLN) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Apr 10, 2010 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for Andrx Corporation (ADRX) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Nov 04, 2006 - HTML - $250.00 - Add to Cart »
- Merger and Acquisition Scenario for AstraZeneca plc (ADR) (AZN) and Valeant Pharmaceuticals International (VRX) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Aug 21, 2010 - HTML - $250.00 - Add to Cart »